UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14-A
(Rule
14A-101)
PROXY
STATEMENT PURSUANT TO SECTION 14(a)
OF
THE SECURITIES AND EXCHANGE ACT OF 1934
Filed by
the Registrant
þ
Filed by
a Party other than the Registrant
o
Check the
appropriate box:
o
Preliminary Proxy
Statement
o
Confidential,
For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive
Proxy Statement
þ
Definitive
Additional Materials
o
Soliciting
Materials Pursuant to Section 240.14a.12
LCA-Vision
Inc.
(Name
of Registrant as Specified in its Charter)
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
þ
No fee
required.
o
Fee computed on
table below per Exchange Act Rules 14a-6(i)(1) and 0-11
|
1)
|
Title
of each class of securities to which the transaction applies:
__________________________________________________________________
|
|
2)
|
Aggregate
number of securities to which transaction applies:
__________________________________________________________________
|
|
3)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
__________________________________________________________________
|
|
4)
|
Proposed
maximum aggregate value of transaction:
__________________________________________________________________
|
|
o
|
Fee
paid previously with preliminary
materials
|
|
o
|
Check
box if any part of the fee is offset by Exchange Act Rule 0-11(a)(2) and
identify the filing for which the offsetting fee was previously
paid. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its
filing.
|
|
1)
|
Amount
Previously Paid:
__________________________________________________________________
|
|
2)
|
Form,
Schedule or Registration No.:
__________________________________________________________________
|
|
3)
|
Filing
Party:
__________________________________________________________________
|
|
4)
|
Date
Filed:
__________________________________________________________________
|
The
following is the transcript of a video made available on various websites on
March 24, 2009.
This is Steve Straus, CEO of LCA-Vision. We are very
pleased to present this next installment of our ongoing series to keep you, our
constituents, up to date on what's happening with LCA Vision and
LasikPlus.
As
always, thank you if you've made comments to the past editions. Rest assured
they are all considered as we continue to execute on our strategy moving
forward.
During
our last video, I told you that there were some new changes coming to the
Company that would make a difference in the way we conduct our
business. Today, I'm proud to announce that after rigorous clinical
research, cost analysis and strategic planning, LCA-Vision has finalized plans
to reduce the number of excimer laser platforms at each of our LasikPlus vision
centers from three to two.
So what
does this mean?
Currently,
in most of our centers, we operate three different excimer lasers from three
different manufacturers. Based on narrow technology parameters in the
past, we have used three lasers to allow us to treat a wide range of patient
conditions. Not surprisingly, technology has improved and we are pleased to be
able to take advantage of this opportunity afforded by these advancements in
excimer laser platform technology. This allows us to reduce the number to two
platforms: Alcon's Wavelight and Abbott Medical Optics' Visx
lasers. With this advanced technology we will continue to treat our
full range of patients.
This
decision follows a first-of-its-kind, rigorous, contralateral, prospective,
randomized study comparable to the rigors of an FDA clinical trial, which was
performed under the supervision of our Medical Advisory Board and an outside
research specialist. While all of the excimer lasers we tested
performed well, we based our decision on a combination of performance and
economic benefits to both our patients and the Company.
By
reducing the number of excimer platforms, we will be able to reduce our
operating expenses in excess of three million dollars a year once the program is
fully executed at the end of the third quarter of this year. This change will
simplify our pricing, free up space in our surgery suites, and streamline
operational processes while never sacrificing quality or safety.
We will
continue to use IntraLase in all of our vision centers.
Using the
two excimer lasers we have chosen, our LasikPlus Vision Centers will still be
able to continue to offer the same great outcomes to our patients with an
expanded range of treatments that includes standard treatment, a custom
wavefront-guided treatment and an optimized treatment.
Importantly,
as this decision process demonstrates we are getting better at involving the
appropriate people in major decisions. For example, before moving
forward with this decision, we involved the Medical Advisory Board in a
meticulous analysis. We also involved the finance team and our MAB
finance committee.
We have
formed an implementation team that includes representation from operations,
marketing, finance, and others so that we can make sure all ideas and concerns
are heard as we roll out the changes over the next 4-5 months.
Please be
assured that we are partnering with two of the premier ophthalmic companies that
are committed to remaining at the forefront of the refractive industry, with a
shared commitment to the highest level of service.
Abbott
Medical Optics and Alcon are leaders in refractive surgery and are well funded
with vast research and development capabilities that will benefit LasikPlus, our
employees and our patients. You will hear more on this in the future
additions.
In the
meantime, I look forward to speaking to you again soon about more exciting news
coming out of LCA-Vision. I hope you found this edition to be helpful
and informative, and look forward to reading any comments you post
below. Until we speak again, I'm Steve Straus. Good
day.
************
Due to
the nature of the Consent process, your voting instruction is extremely
important and time sensitive. LCA-Vision urges all stockholders to
vote their GOLD cards to REVOKE CONSENT on all three
proposals. Please discard any proxy card that you receive from the
Joffe Group. If you have already voted to consent and wish to change
your vote, you have every right to revoke your consent and vote the GOLD
proxy. Only the latest dated card counts.
LCA-Vision
filed its Definitive Consent Revocation Statement (“Consent Revocation
Statement”) with the Securities and Exchange Commission on Monday, February 9,
2009, and copies of the Consent Revocation Statement with a GOLD Consent
Revocation Card were mailed to stockholders beginning February 10,
2009. The Consent Revocation Statement can be obtained immediately
from the SEC’s website at the following link:
http://idea.sec.gov/Archives/edgar/data/1003130/000114420409006021/v139094_defc14a.htm
or from
the Investor Relations section of the Company’s website at
www.lasikplus.com
and
www.lca-vision.com
. Copies
of the Consent Revocation Statement and consent revocation card may also be
obtained from Georgeson Inc.
Additional
Information:
Georgeson
Inc. has been retained by LCA-Vision as consent revocation solicitation agent.
Stockholders with questions are encouraged to call Georgeson toll-free
1-800-457-0109
. Copies of the
Company’s Consent Revocation Statement, and any other documents filed by
LCA-Vision with the SEC in connection with the consent solicitation can be
obtained free of charge from the SEC’s website at
www.sec.gov
, from the
Company’s website at
www.lasikplus.com
and
www.lca-vision.com
,
or from Georgeson.
(MM) (NASDAQ:LCAV)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:LCAV)
Historical Stock Chart
From Jul 2023 to Jul 2024
